700-87-8

Usage

Uses

Used in Organic Synthesis:
2-Methoxyphenyl isocyanate is used as a key intermediate for the synthesis of various organic compounds. Its reactivity allows it to participate in a wide range of chemical reactions, such as nucleophilic addition, substitution, and rearrangement, leading to the formation of diverse chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Methoxyphenyl isocyanate is utilized as a starting material or building block for the development of new drugs and active pharmaceutical ingredients. Its unique structure and reactivity enable the creation of novel drug candidates with potential therapeutic applications.
Used in Agrochemicals:
2-Methoxyphenyl isocyanate is employed as a raw material in the synthesis of agrochemicals, such as pesticides and herbicides. Its ability to form stable and effective compounds makes it a valuable component in the development of crop protection products.
Used in Dye Industry:
In the dye industry, 2-Methoxyphenyl isocyanate is used as an intermediate for the production of various dyes and pigments. Its chemical properties allow for the creation of colorants with specific characteristics, such as brightness, stability, and solubility, which are essential for various applications, including textiles, plastics, and printing inks.

InChI:InChI=1/C8H7NO2/c1-11-8-5-3-2-4-7(8)9-6-10/h2-5H,1H3

Upstream product

• 83943-67-3 o-methoxybenzoyl azide 
• 71-43-2 benzene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 90-04-0 2-methoxy-phenylamine 
• 944336-14-5 C₈H₈ClNO₂ 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 503-38-8 trichloromethyl chloroformate 
• 530-62-1 1,1'-carbonyldiimidazole 
• 75-44-5 phosgene 

Downstream Products

• 113455-45-1 (2-methoxy-phenyl)-carbamic acid-(2-hydroxy-3-piperidino-propyl ester) 
• 14803-73-7 methyl N-(o-methoxyphenyl)-carbamate 
• 101115-54-2 3,3-diethoxy-acrylic acid o-anisidide 
• 107771-07-3 (2-methoxy-phenyl)-carbamic acid-(2-diethylamino-ethyl ester) 
• 113056-95-4 tris(o-methoxyphenyl)isocyanurate 
• 47449-61-6 6β-[3-(2-methoxy-phenyl)-ureido]-penicillanic acid 
• 32772-88-6 N-acetyl-N'-(2-methoxy-phenyl)-urea 
• 28395-95-1 (2-Methoxy-phenyl)-carbamic acid 5-chloro-2-(2,4-dichloro-phenoxy)-phenyl ester 
• 40397-33-9 2-Hydroxy-4,4-dimethyl-6-oxo-cyclohex-1-enecarboxylic acid (2-methoxy-phenyl)-amide 
• 32608-22-3 (2-Methoxy-phenyl)-carbamic acid prop-2-ynyl ester 
• 26724-45-8 (2-Methoxy-phenyl)-carbamic acid 2,6-dichloro-4-[(2,4-dinitro-phenoxyimino)-methyl]-phenyl ester 
• 29209-19-6 2-methyl-1,1,3-trioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[e][1,2]thiazine-4-carboxylic acid 2-methoxy-anilide 
• 36881-74-0 1-methyl-2,2,4-trioxo-1,2,3,4-tetrahydro-2λ⁶-benzo[c][1,2]thiazine-3-carboxylic acid 2-methoxy-anilide 
• 42609-54-1 1-(2-Methoxy-phenyl)-3-(1-methyl-1-phenyl-ethyl)-urea 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship study of pyrrolidine-oxadiazoles as anthelmintics against Haemonchus contortus

Parasitic roundworms (nematodes) are significant pathogens of humans and animals and cause substantive socioeconomic losses due to the diseases that they cause. The control of nematodes in livestock animals relies heavily on the use of anthelmintic drugs. However, their extensive use has led to a widespread problem of drug resistance in these worms. Thus, the discovery and development of novel chemical entities for the treatment of parasitic worms of humans and animals is needed. Herein, we describe our medicinal chemistry optimization efforts of a phenotypic hit against Haemonchus contortus based on a pyrrolidine-oxadiazole scaffold. This led to the identification of compounds with potent inhibitory activities (IC50 = 0.78–22.4 μM) on the motility and development of parasitic stages of H. contortus, and which were found to be highly selective in a mammalian cell counter-screen. These compounds could be used as suitable chemical tools for drug target identification or as lead compounds for further optimization.

Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide

Reported herein is the design, synthesis, and pharmacologic characterization of a class of TRPV1 antagonists constructed on a phenylquinoline platform that evolved from Cinchophen lead. This design composes three sections: a phenylquinoline headgroup attached to an aliphatic carboxamides, which is tethered at a phenyl tail group. Optimization of this design led to the identification of 37, comprising a pyrrolidine linker and a trifluoromethyl–phenyl tail. In the TRPV1 functional assay, using cells expressed hTRPV1, 37 antagonized capsaicin-induced Ca2+ influx, with an IC50 value of 10.2 nM. In the complete mice analgesic model, 37 exhibited better antinociceptive activity than the positive control BCTC in diverse pain models. All of these results suggested that 37 could be considered as a lead candidate for the further development of antinociceptive drugs.

2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone compounds and application thereof

The invention belongs to the technical field of medicines and relates to 2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone compounds and an application thereof. 2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone derivatives comprise stereisomers and pharmaceutically applicable salts of the compounds and have the general structural formula shown in the description, wherein R is described inthe claims and description. The 2-[3-(4-morpholinyl)propylamine]-3-aryl-4-quinolinone derivatives and pharmaceutically applicable acid-added salts of the compounds can be combined with existing medicines or used separately to serve as influenza virus inhibitors to treat influenza and have better curative effects on various type-A influenza in particular.

With anti-tumor effect of a quinazoline-urea derivative and its application (by machine translation)

The present invention relates to a of the general formula (II) anti-tumor function of said quinazoline-urea derivative and its application. The definition of the substituent in the general formula (II) in the specification. This invention, in order to SUO draw non-Buddhist nun and Geftinat compounds as the precursor, retention of SUO draw non-Buddhist nun the pharmocology-carbamido; at the same time, such as in reserved [...] EGFR-TKIs Geftinat, synthesis, and obtain a series of quinazoline-urea derivatives, by the in vitro activity tests, some compounds exhibit excellent anti-tumor activity, such derivatives have high research and utility value. (II). (by machine translation)

Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents

Through a structure-based molecular hybridization approach, a series of novel quinazolinyl-diaryl urea derivatives were designed, synthesized, and screened for their in vitro antiproliferative activities against three cancer cell lines (HepG2, MGC-803, and A549). Six compounds (7g, 7m, 7o, 8e, 8g, and 8m) showed stronger activity against a certain cell line compared with the positive reference drugs sorafenib and gefitinib. Among the six compounds, 8g exhibited the strongest activity. In particular, compound 8g induced A549 apoptosis, arrested cell cycle at the G0/G1 phase, elevated intracellular reactive oxygen species level, and decreased mitochondrial membrane potential. This compound can also effectively regulate the expression of apoptosis- and cell cycle-related proteins, and influence the Raf/MEK/ERK pathway. Molecular docking and structure-activity relationship analyses revealed that it can bind well to the active site of the receptor c-Raf, which was consistent with the biological data. Therefore, compound 8g may be a potent antitumor agent, representing a promising lead for further optimization.

Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors

A number of 1,2-benzisothiazol-3-one derivatives were prepared through structural modification of the original compound from high-throughput screening. Some analogues (e.g., 6b, 6r, 6s and 6w) were identified as novel and potent caspase inhibitors with IC50 of nanomolar. Structure-activity relationship (SAR) studies for caspase-3 inhibition were evaluated in vitro. Molecular modeling studies provided further insight into the interaction of this class of compounds with activated caspase-3. The present small molecule caspase-3 inhibitor with novel structures different from structures of known caspase inhibitors revealed a new direction for therapeutic strategies directed against diseases involving abnormally up-regulated apoptosis.

A simple and efficient synthesis of diaryl ureas with reduction of the intermediate isocyanate by triethylamine

Thirty symmetrical diaryl urea derivatives were synthesised in moderate to excellent yields from arylamine and triphosgene with triethylamine as a reducing agent for the intermediate, isocyanate. It was significant that part of the products could be collected in almost quantitative yield without column chromatography. The procedure under mild reaction conditions was tolerant of a wide range of functional groups. The structures of the compounds were determined by NMR, MS and X-ray crystallographic analyses.

Aryl carbamate derivatives, preperation and use thereof

The present invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, it relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in the field of human and animal health. The compounds according to the invention are preferably 5-HT4 serotoninergic receptor ligands and can therefore be used in the therapeutic or prophylactic treatment of any disorder involving a 5-HT4 receptor. The invention also relates to pharmaceutical compositions comprising such compounds, the preparation and use thereof and treatment methods using said compounds.

Piperidine-containing histamine H3 receptor antagonists of the carbamate series: The influence of the additional ether functionality

Recently novel leads for histamine H3 receptor antagonists of the non-imidazole type have been described. As a continuation of this research eleven new carbamate derivatives possessing an additional ether functionality were prepared. The compounds were evaluated in vitro for their antagonist activity on isolated organs of guinea-pig (GP) H3 as well as H2, H1, and M3 receptors, respectively. All compounds investigated possessed moderate antagonist affinities at guinea-pig histamine H3 receptors (pA2 6.11-6.76). An ether functionality introduced in different places of the lipophilic part of carbamates differently influenced activity and selectivity toward H3, M3, and other histamine receptors tested.

N-substituted hydroxyureas as urease inhibitors

In order to seek a urease inhibitor more potent than hydroxyurea (1), its alkyl- or phenyl-substituted derivatives were synthesized and evaluated for their effect on the jack bean urease. Of 16 compounds tested, m-methyl-(10) and m-methoxy-phenyl substituted hydroxyurea (13) showed the most potent inhibitory activities against the enzyme.